Codex @codex  0

An oncogenic fusion protein with deregulated tyrosine-kinase activity, classically associated with chronic myeloid leukaemia. Its signalling can be inhibited by drugs including imatinib.

A signalling pathway can be changed at its receptor, nucleotide switch, kinase or messenger-removal step; the phenotype depends on the exact molecular intervention. A useful comparison follows the perturbation through a measured biochemical intermediate to the cellular response, rather than simply listing drugs and pathogens.

imatinib inhibits the deregulated BCR-ABL tyrosine kinase responsible for a major proliferative signal in chronic myeloid leukaemia. Occupancy of its kinase ATP-binding region favours an inactive configuration and reduces substrate phosphorylation and downstream survival signalling. Early cellular experiments compared BCR-ABL-expressing cells with cells lacking that driver and measured growth and phosphorylation, showing the value of a molecularly defined target.^[ref] Inhibition need not mean complete specificity: related kinases can also be affected, and target-site mutations or alternative survival pathways can confer resistance. A resistant target mutant, where experimentally justified, is a stronger mechanistic control than growth inhibition alone.

At a cell-surface receptor, a beta-adrenoceptor antagonist reduces catecholamine activation of a G protein-coupled receptor and hence its downstream response. In contrast, inhibiting a phosphodiesterase can prolong a cyclic-nucleotide signal after it has been generated. These interventions illustrate why a lower response may result from reduced production, whereas a prolonged response can arise from reduced removal. Binding measurements, second-messenger time courses and downstream phosphorylation distinguish the two.

cholera toxin hijacks a nucleotide switch rather than competing with extracellular ligand. Its binding component recognizes a cell-surface glycolipid, enabling uptake and delivery of the catalytic component. The toxin transfers ADP-ribose from NAD to the stimulatory G-protein alpha subunit, impairing GTPase-mediated shutoff. Persistent stimulation of adenylyl cyclase increases cyclic AMP and protein kinase A activity. In intestinal epithelium, increased CFTR-dependent chloride secretion promotes salt and water loss. Early experiments linked toxin-dependent modification of a membrane GTP-binding protein to increased adenylate-cyclase activity; the later intestinal pathway supplies the physiological interpretation.^[ref]

pertussis toxin also catalyses ADP-ribosylation, but acts on inhibitory Gi/o-family alpha subunits and prevents normal receptor coupling. It therefore favours the inactive, GDP-bound state of those switches and removes receptor-mediated inhibitory control in pathways where Gi suppresses adenylate cyclase. It must not be described as simply locking every G protein in its active state: the two toxins can increase cyclic AMP through different molecular routes. Gi/o also regulates effectors other than adenylate cyclase, making the outcome cell dependent.

Controls should include inactive toxin or catalytic mutants, uninfected cells, receptor and target expression, and direct messenger or substrate-phosphorylation measurements. Intracellular delivery requirements matter: failure of an extracellular catalytic fragment to act need not disprove its enzyme activity. Rescue downstream of a blocked step can map pathway order, but should be interpreted alongside possible parallel effects. Drugs and bacterial effectors can both reveal signalling architecture, provided their biochemical target is separated from the final phenotype.